Sharps Technology Documents

Sharps Technology SEC Filings

Sharps Technology Documents 2026

Sharps Technology Stock analysis

Sharps Technology Sharps Technology Inc. generates revenue through the development and manufacturing of innovative drug delivery systems, particularly its Sharps Provensa line of smart safety syringes. The company offers products like Sharps Provensa PS-3ML, Sharps Provensa RS-1ML, and Sharps Provensa PSU-0.3 ML, designed to address global healthcare challenges such as minimizing vaccine waste and providing needlestick protection. Its Ultra-Low Waste syringes are specifically marketed to healthcare providers and institutions seeking efficient solutions for vaccine administration. The firm also distributes Sharps Provensa RTF PS Glass Prefillable Syringes, targeting hospitals and clinics that require reliable, pre-filled syringe systems. The company's revenue streams are driven by the commercialization of its patented safety syringe technology, with a focus on healthcare facilities and organizations involved in vaccine distribution. Sharps Provensa PS-1ML and other models are positioned for use in clinical settings where safety and waste reduction are critical. The manufacturing facility, located over 160 kilometers from Budapest Airport, supports production for global distribution, though the business description does not specify exact buyer segments beyond healthcare providers. Safegard Medical, Inc., the wholly owned subsidiary, likely contributes to the company's product portfolio and manufacturing capabilities, though the business description does not detail its specific role in revenue generation. The firm's products are designed to meet the needs of healthcare systems aiming to reduce waste and improve safety, with no mention of additional revenue sources or partnerships beyond its core product lines.